Plastikon Healthcare’s drug manufacturing facility in Lawrence, Kan., drew an 11-observation Form 483 following an FDA inspection in late October-early November that identified several testing and documentation failures.
Source: Drug Industry Daily
Plastikon Healthcare’s drug manufacturing facility in Lawrence, Kan., drew an 11-observation Form 483 following an FDA inspection in late October-early November that identified several testing and documentation failures.
Source: Drug Industry Daily